Latest Conference Articles

Hepatic Steatosis is a Risk Factor for MACE, Even Among Individuals at Low 10-Year ASCVD Risk

Hepatic Steatosis is a Risk Factor for MACE, Even Among Individuals at Low 10-Year ASCVD Risk

November 10th 2023

AASLD The Liver Meeting 2023

TLM 2023: The burden of CAD is similar between persons with hepatic steatosis at low and high ASCVD risk, but rate of MACE is higher in the low-risk population.

Rifaximin Significantly Reduced Recurrent OHE and Associated Health Care Utilization

Rifaximin Significantly Reduced Recurrent OHE and Associated Health Care Utilization

November 10th 2023

AASLD The Liver Meeting 2023

TLM 2023: Use of rifaximin significantly reduced mean number of OHE episodes as well as hospital contacts, including ED visits and admissions.

Statin Protection Against Cirrhosis in Adults with NAFLD More Pronounced with Age

Statin Protection Against Cirrhosis in Adults with NAFLD More Pronounced with Age

November 10th 2023

AASLD The Liver Meeting 2023

TLM 2023: Investigators found that the protective effects of statin therapy against late stage liver disease increased with age older than 51 years.

New Research Reveals Underestimation of Overt Hepatic Encephalopathy Hospitalizations in US

New Research Reveals Underestimation of Overt Hepatic Encephalopathy Hospitalizations in US

November 10th 2023

AASLD The Liver Meeting 2023

TLM 2023: Relying solely on a primary diagnosis for overt hepatic encephalopathy underestimates the actual rate, length of stay, and costs of OHE hospitalizations.

STUDY: Novel “Triagonist” Retatrutide Resolved Steatosis in Over 85% of Patients with MASLD and Obesity

STUDY: Novel “Triagonist” Retatrutide Resolved Steatosis in Over 85% of Patients with MASLD and Obesity

November 10th 2023

AASLD The Liver Meeting 2023

TLM 2023: In participants with metabolic dysfunction-associated steatotic liver disease, retatrutide 8 mg and 12 mg resolved steatosis in >85% of subjects.

It's High Time to Retire NAFLD: Multinational Liver Societies Explain

It's High Time to Retire NAFLD: Multinational Liver Societies Explain

November 8th 2023

AASLD The Liver Meeting 2023

NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.

NAFLD is Now MASLD: The New Nomenclature, At-a-Glance

NAFLD is Now MASLD: The New Nomenclature, At-a-Glance

November 8th 2023

AASLD The Liver Meeting 2023

The shift in naming for diseases historically known as nonalcoholic fatty liver disease will be top of mind at The Liver Meeting 2023. Get a quick look at why.

The Liver Meeting 2023: AASLD Offers "Journey Maps" to Focused Areas of Interest

The Liver Meeting 2023: AASLD Offers "Journey Maps" to Focused Areas of Interest

November 6th 2023

AASLD The Liver Meeting 2023

We took The Liver Meeting's 11 journey maps to educational sessions and focused on 4 that will be of interest to primary care.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

October 25th 2023

IDWeek

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Universal Masking in Health Care Settings: Poised for Return?

Universal Masking in Health Care Settings: Poised for Return?

October 18th 2023

IDWeek

IDWeek 2023: Infectious disease specialist, Gopi Patel, MD, discusses universal masking in health care settings.